AceLink Therapeutics, Inc., a clinical-stage biotech company developing next-generation oral substrate reduction therapies (SRTs), presented interim d ...

Hyperkalemia occurred in three patients in the ramipril and one patient in the metoprolol randomization group. Ramipril was the only ACE inhibitor employed in the AASK study and angiotensin ...

Dosage varied with the clinical situation and the degree of hyperkalemia. Whenever feasible, the resin was given orally in divided doses, totaling 20 to 60 gm. per day. The resin, a finely ground ...

Copyright: © 2024 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.

The pathophysiology of how hyperkalemia develops is typically ... In a recent comparison of the ACE inhibitor lisinopril with the ARB valsartan in patients with renal insufficiency or diabetes ...

AccurKardia's AK+ Guard is designed to work with a wide range of FDA-cleared consumer and clinical wearables that currently capture Lead I ECG data (e.g., smartwatches), enabling hyperkalemia ...

The investigational technology uses Lead I ECG data to alert patients and clinicians of moderate to severe episodes of hyperkalemia (excess potassium in the blood) that can lead to sudden cardiac ...

This real‐world evidence study compared risks of cardiovascular events in hospital settings among patients with chronic kidney disease (CKD) with and without hyperkalemia. Adults with CKD stages 3b/4 ...

The earlier trial also showed advantages over enalapril on hospitalisation and death rates when patients switched from an ACE inhibitor – enough to get Novartis’ drug included in treatment ...

Recent clinical trials suggest that patients treated with β-blockers and ACE inhibitors are particularly susceptible to destabilization of BP control by some COX-2 inhibitors compared with patients ...